News stories about National CineMedia (NASDAQ:NCMI) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. National CineMedia earned a news impact score of 0.13 on Accern’s scale. Accern also gave media coverage about the business services provider an impact score of 47.2798059004655 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:
Top 5 Clean Energy Stocks To Watch Right Now: Healthcare Realty Trust Incorporated(HR)
Healthcare Realty Trust Incorporated is an independent real estate investment trust. The firm invests in real estate markets of the United States. It primarily engages in ownership, acquisition, management, leasing, and development of properties associated with delivery of healthcare services such as medical office and outpatient facilities. The firm also provides mortgage financing on healthcare facilities. Healthcare Realty Trust Incorporated was formed in 1992 and is based Nashville, Tennessee.
Get a free copy of the Zacks research report on Healthcare Realty Trust (HR) For more information about research offerings from Zacks Investment Research, visit Zacks.com Fiduciary Financial Services of The Southwest Inc. TX reduced its holdings in Healthcare Realty Trust Inc (NYSE:HR) by 6.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 27,551 shares of the real estate investment trust’s stock after selling 2,045 shares during the period. Fiduciary Financial Services of The Southwest Inc. TX’s holdings in Healthcare Realty Trust were worth $806,000 at the end of the most recent quarter. New Mexico Educational Retirement Board lessened its holdings in Healthcare Realty Trust Inc (NYSE:HR) by 14.8% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 29,300 shares of the real estate investment trust’s stock after selling 5,100 shares during the period. New Mexico Educational Retirement Board’s holdings in Healthcare Realty Trust were worth $852,000 at the end of the most recent quarter. Reading International, Inc., a Nevada corporation ("RDI" and collectively with our consolidated subsidiaries and corporate predecessors, the "Company," "Reading" and "we," "us," or "our"), was incorporated in 1999 incident to our reincorporation in Nevada. Our class A non-voting common stock ("Class A Stock") and class B voting common stock ("Class B Stock") are listed for trading on the NASDAQ Capital Market (Nasdaq-CM) under the symbols RDI and RDIB, respectively. Our principal executive offices are located at 6100 Center Drive, Suite 900, Los Angeles, California 90045. Our general telephone number is (213) 235-2240 and our website is www.readingrdi.com. Advisors' Opinion: RDI Reit (LON:RDI) had its price target upped by JPMorgan Chase & Co. from GBX 41 ($0.54) to GBX 205 ($2.68) in a report released on Wednesday. The firm currently has a neutral rating on the stock. Peel Hunt restated their buy rating on shares of RDI Reit (LON:RDI) in a report published on Thursday. RDI stock opened at GBX 32.50 ($0.42) on Thursday. RDI Reit has a fifty-two week low of GBX 33.25 ($0.43) and a fifty-two week high of GBX 40.95 ($0.53). Get a free copy of the Zacks research report on Reading International, Inc. Class A (RDI) For more information about research offerings from Zacks Investment Research, visit Zacks.com Get a free copy of the Zacks research report on Reading International (RDI) For more information about research offerings from Zacks Investment Research, visit Zacks.com Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for liver diseases and cancers based on a proprietary RNA interference technology platform in the United States and internationally. The company's development programs include DCR-PH1 for the treatment of primary hyperoxaluria type 1 (PH1) through targeting the gene encoding the liver enzyme glycolate oxidase; and other rare inherited diseases involving genes expressed in the liver. It is also developing DCR-MYC, which is in Phase I clinical study for the treatment of various cancers in patients with solid tumors, multiple myeloma, or lymphoma, as well as in Phase Ib/II clinical trial to treat cancer in patients with advanced hepatocellular carcinoma. In addition, the company is developing KRAS oncogene, a gene that is mutated in various cancers, including non-small cell lung cancer, colorectal cancer, and pancreatic cancer; and a therapeutic targeting a second cancer-related gene. It has a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd. for the research, development, and commercialization of Dicer substrate short interfering RNAs (DsiRNA) molecules and drug delivery technologies for therapeutic targets in oncology; license agreement with City of Hope, an academic research and medical center to manufacture, use, offer for sale, sell, and import products related to DsiRNA for the prevention and treatment of various diseases in humans; and license agreement with Plant Bioscience Limited to research, discover, develop, manufacture, sell, import, and export products incorporating short RNA molecules. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) – Equities research analysts at B. Riley issued their Q1 2019 earnings per share estimates for shares of Dicerna Pharmaceuticals in a report released on Tuesday, March 12th. B. Riley analyst M. Mamtani anticipates that the biopharmaceutical company will earn ($0.22) per share for the quarter. B. Riley has a “Buy” rating and a $24.00 price target on the stock. B. Riley also issued estimates for Dicerna Pharmaceuticals’ Q2 2019 earnings at ($0.23) EPS, Q3 2019 earnings at ($0.24) EPS, Q4 2019 earnings at ($0.26) EPS, FY2019 earnings at ($0.96) EPS, FY2020 earnings at ($1.48) EPS and FY2021 earnings at ($1.51) EPS. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)Q4 2018 Earnings Conference CallMarch 11, 2019, 4:30 p.m. ET Operator Get a free copy of the Zacks research report on Dicerna Pharmaceuticals (DRNA) For more information about research offerings from Zacks Investment Research, visit Zacks.com Dicerna Pharmaceuticals (NASDAQ:DRNA) had its target price upped by research analysts at B. Riley from $10.00 to $13.50 in a research note issued on Monday, Stock Target Advisor reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. B. Riley’s price target indicates a potential downside of 20.26% from the company’s current price. MIND C.T.I. Ltd., together with its subsidiaries, develops, manufactures, implements, and markets real-time and off-line billing and customer care software solutions in the Americas, the Asia Pacific, Africa, Europe, and Israel. The company offers billing and customer care solution that supports services, such as voice, data, and content services, as well as prepaid, postpaid, and pay-in-advance payment models in a single platform. Its solution also includes a workflow engine to support the implementation of business processes, including subscriber registration, order management, trouble ticket, and debt collection; and an integral point of sale solution that covers all dealer, store and cashier management, and sales processes. In addition, the company offers professional services comprising installation, turnkey project implementation services, customer support, training and maintenance services, software and process customization, and project management, as well as managed services, including day to day billing operational tasks primarily to its billing and customer care customers. Further, it provides call management systems comprising PhonEX and MEIPS, which collects, records, and stores call information in a customized database; and enterprise software products, such as PhonEX-Ten and PhonEX-ONE that are used by corporations for telecom expense management, call accounting, traffic analysis, and fraud detection. The company offers its products directly; and through network equipment vendors and systems integrators, and resellers primarily to communication providers, such as traditional wireline and wireless, voice over IP, broadband IP network operators, LTE operators, cable operators, and mobile virtual network operators. MIND C.T.I. Ltd. was founded in 1995 and is headquartered in Yokneam Illit, Israel. TRADEMARK VIOLATION NOTICE: “MIND C.T.I. Ltd. Declares Annual Dividend of $0.26 (MNDO)” was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/4210875/mind-c-t-i-ltd-declares-annual-dividend-of-0-26-mndo.html. XO Group Inc. provides consumer Internet multiplatform media services to the wedding, pregnancy and parenting, and nesting markets. It operates a network of Websites under various brands, such as The Knot, which offers wedding resources through wedding Website and mobile apps, national and local wedding magazines, and nationally published books; The Bump, a pregnancy and parenting brand that provides personalized information, content, and tools for anyone at any stage of their journey from fertility to pregnancy and parenting through the toddler years; and The Nest, which focuses on young nesters setting up homes and navigating new lives together. The company also offers national online advertising products, including sponsored and brand-integrated content, digital banner advertisements, native banner advertising, and direct e-mail marketing; local online advertising products comprising digital advertisements and direct e-mail marketing; and registry and commerce, a Website that allows couples the opportunity to create, manage, and share multiple retail store registries from a single source. In addition, it publishes The Knot Weddings and The Bump magazines. The company was formerly known as The Knot, Inc. and changed its name to XO Group Inc. in June 2011. XO Group Inc. was founded in 1996 and is headquartered in New York, New York. SinglePoint (OTCMKTS:SING) and XO Group (NYSE:XOXO) are both small-cap computer and technology companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk. ValuEngine upgraded shares of XO Group (NYSE:XOXO) from a buy rating to a strong-buy rating in a research report sent to investors on Wednesday morning. Shares of XO Group Inc. (NYSE:XOXO) were up 26% as of 3:00 p.m. EDT Tuesday after the parent company of The Knot agreed to merge with WeddingWire, Inc. in a deal valued at $933 million. Top 5 Clean Energy Stocks To Watch Right Now: Reading International Inc(RDI)
Top 5 Clean Energy Stocks To Watch Right Now: Dicerna Pharmaceuticals, Inc.(DRNA)
Top 5 Clean Energy Stocks To Watch Right Now: MIND C.T.I. Ltd.(MNDO)
Top 5 Clean Energy Stocks To Watch Right Now: XO Group, Inc.(XOXO)
No comments:
Post a Comment